Syndecan Interactions in Lung Injury and Repair
Syndecan Interactions in Lung Injury and Repair
批准号:
8259421
负责人:
Pyong Woo Park
金额:
$43.5万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-01 至 2015-02-28
关键词:
AcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAnimal ModelApplications GrantsAttenuatedBindingBiologyCXCL1 geneCell surfaceComplexDataDevelopmentDiseaseDisease ProgressionEndogenous FactorsEndotoxic ShockEnvironmentEpithelialFailureFamilyFoundationsFunctional disorderGlycosaminoglycansGoalsGrantHealedHeparan Sulfate ProteoglycanHeparitin SulfateHost Defense MechanismInfectionInflammationInflammation MediatorsInflammatoryInflammatory ResponseInfusion proceduresKnockout MiceLeadLigand BindingLigandsLigationLungLung InflammationLung diseasesMetalloproteasesModificationMolecularMolecular TargetMorbidity - disease rateMusNeutrophil InfiltrationPatientsPhasePuncture procedureResolutionRoleSepsisSourceT-LymphocyteTestingTherapeuticTimeLineTissuesToxic Shock SyndromeWild Type Mouseattenuationbasedesignextracellularhealingimprovedkillingslung injurylung repairmortalitynovel therapeutic interventionpublic health relevanceresponse to injurysepticsyndecan
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The central goal of this proposal is to define how syndecan interactions modulate lung injury responses in systemic inflammatory diseases. Dysregulated lung injury responses to systemic inflammatory diseases, such as sepsis, can lead to acute lung injury (ALI) and are a major cause of morbidity and mortality. However, many patients survive the initial phase of lung injury and do not progress to ALI or to the more severe form of ALI, acute respiratory distress syndrome (ARDS). These data suggest the importance of endogenous protective mechanisms that attenuate or reverse disease progression, but the underlying biology remains to be elucidated. Syndecans comprise a major family of cell surface heparan sulfate proteoglycans (HSPGs). Syndecans function as coreceptors on the cell surface and also as soluble HSPGs in the extracelular environment because its ectodomain can be shed under inflammatory conditions. Syndecans bind to ligands through its heparan sulfate (HS) chains, a glycosaminoglycan that binds to and regulates several inflammatory mediators implicated in lung injury. However, the precise role of syndecan interactions in inflammatory lung injury has yet to be determined. Syndecan-1 null mice show increased lung injury and mortality when subjected to animal models of systemic inflammatory diseases, such as endotoxic shock, Gram-positive toxic shock, or sepsis. Syndecan-1 shedding is induced in the lungs of wild type mice by the systemic inflammatory challenge, and inhibition of shedding exacerbates lung injury, whereas administration of purified syndecan-1 ectodomain or HS improves disease parameters. Based on these data, this proposal will examine the overall hypothesis that syndecan-1 modulates, in part, the highly complex mechanisms of lung injury and repair in systemic inflammatory diseases in 3 Specific Aims. Aim 1 wil define how syndecan-1 facilitates the resolution of lung inflammation. Aim 2 will determine how syndecan-1 attenuates lung injury and inflammation in sepsis. Aim 3 will establish that temporal syndecan-1 interactions regulate its shedding at the cell surface. These studies should define the key functions of syndecans in lung injury and repair, and provide a mechanistic foundation for the design and development of new therapeutic approaches against inflammatory lung diseases.
PUBLIC HEALTH RELEVANCE: Correctly coordinated inflammation protects from infection and helps heal tissues. However, excessive and inappropriate inflammation can damage tissues and lead to serious complications associated with high morbidity and mortality, such as lung injury, dysfunction, and failure. This grant application will investigate how one of our own molecules called syndecan corrects the dysregulated inflammatory response in the lung, with the goal of identifying new molecular targets for the effective therapeutic control of inflammatory lung diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HSPG Interactions in Liver Disease
-
批准号:10595653
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2022
-
负责人:Pyong Woo Park
-
依托单位:
HSPG Interactions in Liver Disease
-
批准号:10446447
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2022
-
负责人:Pyong Woo Park
-
依托单位:
ECM Regulation of Ocular Surface Disease
-
批准号:10445477
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2022
-
负责人:Pyong Woo Park
-
依托单位:
ECM Regulation of Ocular Surface Disease
-
批准号:10598138
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2022
-
负责人:Pyong Woo Park
-
依托单位:
Subversion of Syndecan-1 Functions in Listeriosis
-
批准号:10318671
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2020
-
负责人:Pyong Woo Park
-
依托单位:
Syndecan Regulation of Sepsis Host Defense
-
批准号:10191013
-
项目类别:
-
资助金额:$50.14万
-
财政年份:2018
-
负责人:Pyong Woo Park
-
依托单位:
Syndecan Regulation of Sepsis Host Defense
-
批准号:9759980
-
项目类别:
-
资助金额:$50.14万
-
财政年份:2018
-
负责人:Pyong Woo Park
-
依托单位:
HSPGs in Alpha-toxin-induced Tissue Injury
-
批准号:9280796
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2016
-
负责人:Pyong Woo Park
-
依托单位:
HSPGs in Ocular Surface Diseases
-
批准号:8578101
-
项目类别:
-
资助金额:$38.37万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
Syndecan Interactions in Lung Injury and Repair
-
批准号:8086196
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
HSPGs in Ocular Surface Diseases
-
批准号:8238954
-
项目类别:
-
资助金额:$39.15万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
HSPGs in Ocular Surface Diseases
-
批准号:8389902
-
项目类别:
-
资助金额:$37.19万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
HSPGs in Ocular Surface Diseases
-
批准号:8773593
-
项目类别:
-
资助金额:$38.37万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
Syndecan Interactions in Lung Injury and Repair
-
批准号:8610344
-
项目类别:
-
资助金额:$42.63万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
Syndecan Interactions in Lung Injury and Repair
-
批准号:8423742
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2011
-
负责人:Pyong Woo Park
-
依托单位:
Proteoglycans in Lung Innate Immunity and Host Defense
-
批准号:8269945
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2009
-
负责人:Pyong Woo Park
-
依托单位:
Proteoglycans in Lung Innate Immunity and Host Defense
-
批准号:7729294
-
项目类别:
-
资助金额:$42.67万
-
财政年份:2009
-
负责人:Pyong Woo Park
-
依托单位:
Role of Syndecan-1 in S. aureus Pneumonia
-
批准号:7896465
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2009
-
负责人:Pyong Woo Park
-
依托单位:
Role of Syndecan-1 in S. aureus Pneumonia
-
批准号:7700398
-
项目类别:
-
资助金额:$25.58万
-
财政年份:2009
-
负责人:Pyong Woo Park
-
依托单位:
Proteoglycans in Lung Innate Immunity and Host Defense
-
批准号:8076806
-
项目类别:
-
资助金额:$43.42万
-
财政年份:2009
-
负责人:Pyong Woo Park
-
依托单位:
海外基金